Physician profile
Gary J Stadtmauer
NPI 1669567814
$5,106.11
in general payments reported to CMS, 2019-2025
16 companies · $717 in 2025
The $717 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $1,978 · 2021: $233 · 2022: $342 · 2023: $603 · 2024: $826 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920 · Education: $121 · Debt Forgiveness: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.85 |
| Education | $121.00 |
| Debt Forgiveness | $104.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,940.00 | 2020 | |
| Glaxosmithkline, LLC. | $733.64 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $646.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $571.02 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Kaleo, INC. | $361.11 | 2022-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $203.34 | 2019-2025 | |
| Amgen INC. | $158.76 | 2021-2025 | Tezspire |
| Baxter Healthcare | $104.88 | 2023 | |
| Sanofi-Aventis U.S. LLC | $95.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.92 | 2024-2025 | Hyqvia |
| Grifols USA, LLC | $57.86 | 2025 | Xembify |
| Optinose US, INC. | $51.75 | 2022-2025 | |
| Alk-Abello, INC | $34.96 | 2019 | |
| Incyte Corporation | $23.20 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $22.57 | 2025 | Neffy |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18.75 | 2023 | Rinvoq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Stadtmauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.